Nel ASA: Nel Launches MC250 and MC500 Containerized Large-Scale PEM Electrolysers
Nel Hydrogen Electrolyser, a subsidiary of Nel ASA (Nel, OSE:NEL), has launched the MC250 and MC500 containerized Proton PEM electrolysers.
“We are proud to officially launch the MC250 and MC500, representing automated MW-class on-site hydrogen generators utilizing a modular containerized design for ease of installation and integration. Nel is pleased to expand our product offering with additional two world-class hydrogen generators and we are already experiencing significant interest for these solutions in the market,” says Filip Smeets, SVP Electrolyser Division of Nel.
The containerized MC250 and MC500 will be delivered as standard 1.25 and 2.5 MW (246 and 492 Nm3/h) configurations respectively. The new products are integrating Nel’s newly developed 1.25 MW PEM cell-stack, allowing for higher capacities per unit and lower cost. The platform allows multiple units to be integrated easily in the field, which was a key consideration during the development.
“We are paying close attention to the market and our customers’ needs. With the containerized M Series PEM electrolysers, we are offering the same robustness and reliability of our conventional M Series units, enabling faster and more flexible installation,” Smeets concludes.
About Nel ASA | www.nelhydrogen.com
Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store, and distribute hydrogen from renewable energy. We serve industries, energy, and gas companies with leading hydrogen technology. Our roots date back to 1927, and since then, we have had a proud history of development and continuous improvement of hydrogen technologies. Today, our solutions cover the entire value chain: from hydrogen production technologies to hydrogen fueling stations, enabling industries to transition to green hydrogen, and providing fuel cell electric vehicles with the same fast fueling and long range as fossil-fueled vehicles - without the emissions.
Steve Szymanski, VP Sales and Marketing, Americas, +1.203.980.3182
Raymond Schmid, VP sales and Marketing, EMA, +41.76.334.76.54
Or email email@example.com
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Universal Peace Federation: Millions of participants from 150 countries joined the live online broadcast of the 5 th Rally of Hope3.3.2021 19:43:00 CET | Press release
Millions of participants from 150 countries joined the live online broadcast of the 5th Rally of Hope sponsored by the Universal Peace Federation (UPF) on Saturday, February 27, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005853/en/ Dr. Hak Ja Han Moon, Co-Founder of Universal Peace Federation delivering her message of peace to the online participants of the 5th Rally of Hope. (Photo: Business Wire) The virtual event featured world-class entertainment and globally renowned leaders including Cape Verde President Jorge Carlos Fonseca; Guyana Prime Minister Mark Phillips; U.S. Vice President Mike Pence (2017-2021); United Nations World Food Programme Executive Director David Beasley; City of Refuge Church Bishop Noel Jones; South Africa President F.W. de Klerk (1989-1994); India Vice President Mohammad Hamid Ansari (2007-2017); Oxford Vaccine co-developer Dr. Sarah Gilbert; and East Timor President Xanana Gusmão
AGCO Announces Farmer-First Strategy3.3.2021 17:50:00 CET | Press release
AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology, today announced its farmer-first strategy designed to maximize value creation for its key stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005773/en/ AGCO Announces Farmer-First Strategy (Photo: Business Wire) During its 2021 Virtual Analyst Briefing, Eric Hansotia, AGCO’s Chairman, President and CEO introduced AGCO’s new Purpose and Vision statements that, when combined, offer powerful insight into the role AGCO intends to play for farmers and within the agriculture industry. AGCO’s Purpose is to deliver “Farmer-focused solutions to sustainably feed our world” and its Vision is to be the “Trusted partner for industry-leading, smart farming solutions.” AGCO will realize its Purpose and Vision by continuing to leverage its award-winning, differentiated brand portfolio to offer
Norwegian Emergency Health Services Gain Nationwide Collaboration Through Motorola Solutions’ Unified Control Room Solution3.3.2021 17:27:00 CET | Press release
Health services are a critical discipline, where every second counts and the control room is at the heart of their mission-critical operations. Teams require collaboration and flexibility to effectively manage emergency health situations as they arise. This has become especially apparent with the ongoing COVID-19 pandemic, where pressures on health services including medical communication centres, continue to rise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005158/en/ (Photo: Business Wire) Motorola Solutions announced today it has been awarded a contract by Helsetjenestens Driftsorganisasjon for Nødnett HF (HDO HF) to provide the Norwegian Health Emergency Service with a new CommandCentral Control Room Solution (CRS). “The new control room solution allows for significant improvements to efficiency and scalability, providing the much-needed flexibility between mission-critical teams”, said Lars Erik Tandsæther, CEO
H.I.G. Capital Expands European WhiteHorse Team with the Addition of Michael Lucas3.3.2021 17:08:00 CET | Press release
H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with over €35 billion of equity capital under management, is pleased to announce the expansion of its European WhiteHorse team with the addition of Michael Lucas as a Managing Director. Michael will be based in H.I.G.’s London office. Michael has 27 years of experience in leveraged finance and direct lending. Prior to joining H.I.G., he was a Founding Partner and Head of the UK at Bridgepoint Credit. Prior to that, he spent over 20 years at ING where he was most recently acting as Global Head of Financial Sponsors. Commenting on the hire, Pascal Meysson, Head of H.I.G. WhiteHorse Europe, said, “We are thrilled to have Michael join the firm. He is one of the most respected and well-known professionals within the direct lending community in Europe, and I am confident he will have an immediate impact on our growing European direct lending platform.” About H.I.G. Capital H.I.G. is a leading global alternative asse
NZMP™ Customers Set to Benefit From New Carbonzero Certified Ingredients3.3.2021 17:00:00 CET | Press release
NZMP™, Fonterra’s dairy ingredient and solutions brand, has launched a new carbonzero certified Organic Butter. Debuting its launch in North America, the new Organic Butter will help NZMP’s customers to achieve their own sustainability goals and meet consumer demand for more sustainable products. With 72 per cent of global consumers expressing an interest in brands that actively communicate achievements around sustainability1, the introduction of carbonzero ingredients is just one way in which NZMP™ customers can leverage Fonterra’s sustainability solutions. NZMP’s™ first certified carbonzero ingredient has been audited and verified by Toitū Envirocare, an independent certifier. Lara Phillips, Senior Manager of Fonterra Sustainability Solutions, says: “Climate change is one of the most pressing challenges of our time and we’re committed to finding solutions to reduce our footprint further as part of our ongoing journey in sustainability. “To obtain carbonzero certification for an ingre
CORRECTING and REPLACING Monument Re Acquires Variable Annuity Portfolio From Athora Ireland Plc.3.3.2021 16:07:00 CET | Press release
Headline of release should read: Monument Re Acquires Variable Annuity Portfolio From Athora Ireland Plc. (instead of Monument Re Acquires Variable Annuity Portfolio From Athora Life Plc.). The updated release reads: MONUMENT RE ACQUIRES VARIABLE ANNUITY PORTFOLIO FROM ATHORA IRELAND PLC. Monument Re announced today that, subject to necessary Irish High Court and regulatory approvals, it has agreed to acquire the closed-block portfolio of variable annuities from Athora Ireland plc, a wholly-owned subsidiary of Athora Holding Ltd. Financial terms of the transaction were not disclosed. “We are pleased to have reached agreement with Athora to acquire this block of business which further reinforces our position as the market leading consolidator in Ireland,” said Manfred Maske, CEO of Monument Re. About Athora Holding Ltd. Athora is a specialised insurance and reinsurance group fully focused on the European market. Athora dedicates its focus, capital, time and technical insights to offerin
Altasciences Conducts Phase I Study in Healthy Normal Subjects for RLS-0071 for Treatment of Acute Lung Injury Due to COVID-19 Pneumonia3.3.2021 15:41:00 CET | Press release
Altasciences is pleased to support ReAlta Life Sciences by conducting a Phase I trial to evaluate RLS-0071 for treatment of Acute Lung Injury (ALI) as a result of viral infections, such as COVID-19, respiratory syncytial virus (RSV), and influenza. As part of the ReAlta ALI program underway, the Phase I trial is a single-ascending dose, randomized, double-blind, placebo-controlled, adaptive-design study to evaluate the safety, tolerability, PK, and PD of RLS-0071 in healthy subjects, performed at the Altasciences clinical pharmacology unit in Montreal, Canada. Ingrid Holmes, Vice President, Global Clinical Operations at Altasciences, says, “Our teams are proud to have the opportunity to be involved in the clinical conduct and bioanalytical analysis for this important first-in-human trial. Being able to prioritize COVID-19 therapies by contributing critical data to the development of potentially life-altering medications, such as RLS-0071, is tremendously rewarding to our teams.” Click